GoodRx Holdings

GDRX · NASDAQ

$3.52+$0.15 (+4.45%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $3.37

GDRX analyst rating

HoldConsensus of 9 analysts over the last 12 months. 33% rate it a buy.

Strong buy0
Buy3
Hold5
Underperform1
Sell0

12-month price target · 14 analysts

Average $4.03 (+14.5% upside)

Low: $2.68
Now: $3.52
High: $5.25

Upgrades and downgrades

The latest rating actions, newest first

GDRX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Barclays	Aug 21, 2026	Maintains	Underweight	$3.00 → $4.00	53%
UBS	Aug 13, 2026	Maintains	Neutral	$2.50 → $3.75	70%
Citigroup	Aug 11, 2026	Maintains	Buy	$4.00 → $5.00	44%
TD Cowen	Aug 11, 2026	Maintains	Buy	$4.00 → $5.00	62%
Wells Fargo	Aug 7, 2026	Maintains	Overweight	$3.50 → $5.00	48%
Citigroup	May 14, 2026	Maintains	Buy	$3.50 → $4.00	44%
TD Cowen	May 11, 2026	Maintains	Buy	$3.00 → $4.00	62%
Wells Fargo	Mar 4, 2026	Maintains	Overweight	$7.00 → $3.50	48%
Citigroup	Mar 3, 2026	Maintains	Buy	$4.50 → $3.50	44%
Goldman Sachs	Mar 2, 2026	Maintains	Neutral	$4.00 → $2.50	55%

The case for and against

Updated Nov 27, 2024

Bull case

GoodRx Holdings Inc. has revised its revenue growth expectations for 2024 to a mid-single-digit percentage (MSD%), reflecting an improvement from its prior range of approximately 2.1-5.4%, indicating a potential for stronger performance than consensus estimates. This optimistic outlook is supported by a superior margin profile and increased utilization from seasonal factors and strategic initiatives such as retailer direct contracting. Furthermore, the company's 4Q23 revenue exceeded consensus by 2.7%, reinforcing the positive trajectory and potential for re-accelerated growth in both its membership and manufacturer solutions business.

Bear case

GoodRx Holdings Inc. faces multiple headwinds, including a significantly reduced revenue growth outlook for 2024 projected at only 2-5%, compounded by ongoing issues with declining volumes at Kroger and uncertainty surrounding the company's revenue guidance, which was approximately 6.5% below consensus estimates. Additionally, the company's growth may be adversely affected by the delayed launch of important programs, such as the ESI program and the Caremark program, which could limit its competitive positioning in the market. Furthermore, changes in the regulatory environment and the potential for increased competition from employers offering free generics threaten GoodRx's ability to sustain its revenue and profitability moving forward.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.